Nuformix PLC (NFXN)

London
1.1500
-0.0250(-2.13%)
  • Volume:
    2,120,075
  • Bid/Ask:
    0.0000/0.0000
  • Day's Range:
    1.1500 - 1.1500

NFXN Overview

Prev. Close
1.175
Day's Range
1.15-1.15
Revenue
200K
Open
1.15
52 wk Range
1.12-4.3749
EPS
0
Volume
2,120,075
Market Cap
6.8M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
3,337,581
P/E Ratio
-
Beta
0.81
1-Year Change
-63.49%
Shares Outstanding
591,609,368
Next Earnings Date
-
What is your sentiment on Nuformix PLC?
or
Market is currently closed. Voting is open during market hours.

Nuformix PLC News

  • Nuformix CEO to step down
    • ByProactiveinvestors-

    Nuformix PLC (LON:NFX) said its chief executive Anne Brindley has decided to step down from her role. The pharmaceutical development firm said Brindley will continue in her current...

  • Nuformix says drug pipeline is 'building momentum'
    • ByProactiveinvestors-

    Nuformix PLC (LON:NFX) chief executive Anne Brindley said fundraises in the past year have allowed the pharmaceutical company to develop its pipeline of repurposed drug assets and...

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellSellSellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Nuformix PLC Company Profile

Nuformix PLC Company Profile

Employees
3

Nuformix PLC, formerly Levrett PLC, is a United Kingdom-based pharmaceutical development company. The Company uses cocrystal technology to develop drugs with programs in oncology supportive care and fibrosis. It uses cocrystal technology to re-engineer the crystalline form of drugs. Its clinical pipeline includes NXP001 and NXP002. Its pre-clinical pipeline includes NXP003. It is developing NXP001 for oncology supportive care. It is developing NXP002 for the treatment of multiple fibrotic diseases. NXP003 targets a mechanism understood to confer resistance to immuno-oncology, chemotherapy and radiotherapy cancer treatments.

Read More
  • 100% Bullish Here
    2
    • Strong buy...so much positive news. due q1
      5
      • What news? Never came...
        1
    • Nice to see a positive rns onwards and upwards
      2
      • much more to come. Hold for next waves. sales news and other milestones such as NX0002
        0
        • This could seriously do multiples of current SP.
          2
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.